Published by Josh White on 11th December 2025
(Sharecast News) - Faron Pharmaceuticals said on Thursday that its board had approved the issue of the second tranche of its amortising senior unsecured convertible bonds to an entity managed by Heights Capital Management, raising €10m to extend its cash runway and strengthen its financial position ahead of a planned registrational study in high-risk myelodysplastic syndromes.